Arvinas Dosed First Patient in Oncology Trial

The company has launched a Phase 1/2 trial to test the cancer drug candidate ARV-6723 in adults with advanced solid tumors.

Updated on Sept. 28, 2026 in Biotech

Isometric editorial illustration of a stylized molecular structure and laboratory glassware, symbolizing biotechnology research. — Arvinas has dosed the first patient in a Phase 1/2 clinical trial testing ARV-6723, a new immuno-oncology drug candidate. AI Illustration. Upload story photo >

Live Poll

Would you consider participating in an experimental clinical trial for a cancer treatment?

Arvinas has officially dosed the first patient in a clinical trial for ARV-6723, its new oral PROTAC drug candidate designed to degrade the HPK1 protein. This study marks the company's first move into the immuno-oncology space as it evaluates the treatment in patients with advanced solid tumors.

Why it matters

HPK1 acts as a negative regulator of immune cell activation, and by degrading this protein, the drug seeks to boost the body's natural antitumor response. This approach is intended to provide therapeutic benefits, particularly for patients whose tumors have been resistant to existing immune checkpoint inhibitors.

The clinical trial, identified as NCT07749586, evaluates the drug as a monotherapy or in combination with pembrolizumab. Researchers are measuring safety, pharmacokinetics, and pharmacodynamics to assess the potential of the PROTAC candidate.

The players

Arvinas

A biopharmaceutical company headquartered in New Haven, Connecticut, that focuses on developing protein degradation therapeutics.

The details

The drug candidate ARV-6723 targets the HPK1 protein, which hinders T cells, B cells, and natural killer cells. The current study assesses whether deep and sustained degradation of this target protein can effectively translate into meaningful clinical antitumor effects.

Arvinas announced the first patient dosing on September 28, 2026.

Biotech
Sept. 21
ADARx Pharmaceuticals Targeted $1.74 Billion IPO Valuation
Cancer
Sept. 24
Sellas Life Sciences Shares Slipped Overnight
Biotech
Sept. 18
Biotech Firms Filed For Initial Public Offerings

The Tech Race

This development highlights the ongoing shift toward using protein degradation to address biological targets that were previously considered undruggable. It positions Arvinas as a competitor in the race to develop potent immuno-oncology treatments that overcome traditional checkpoint resistance.

This trial represents the early research phase for a new oncology treatment, meaning it does not currently change standard care or drug availability for the general public. Future results will determine if this approach provides a viable new treatment option for patients with advanced solid tumors.

The takeaway

The initiation of this trial highlights the transition of protein-degrading technology from preclinical models to human testing. If successful, this mechanism could offer a new pathway for managing tumors that do not respond to currently approved immunotherapies.